AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line treatment in HER2-positive breast cancer after recording “highly ...

Enhertu plus Perjeta showed significant improvement in progression-free survival in HER2-positive metastatic breast cancer patients compared to standard treatment. The DESTINY-Breast09 trial is the ...

AstraZeneca and Daiichi Sankyo are preparing regulatory filings that could make their HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the ...

AstraZeneca (NASDAQ:AZN) said on Monday that the late-stage trial for Enhertu, in combination with pertuzumab, showed significant improvement as a first line treatment of metastatic breast cancer ...

DESTINY-Breast09 Phase III trial of AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive ...

But the companies said Monday that the planned interim analysis showed the drug, Enhertu, led to a “highly statistically significant and clinically meaningful improvement in progression-free ...

A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved in the UK. This drug is designed to help adults with certain types of advanced cancer that cannot be ...

(RTTNews) - Daiichi Sankyo Co., Ltd. (DSKYF.PK) announced Monday that Enhertu (trastuzumab deruxtecan), co-developed and commercialized with British drug major AstraZeneca Plc. (AZN.L, AZN), Plus ...

A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved in the UK. This drug is designed to help adults with certain types of advanced cancer that cannot be ...

Topline results from a planned interim analysis of the DESTINY-Breast09 phase 3 trial showed Enhertu in combination with pertuzumab demonstrated a highly statistically significant and clinically ...

Amid these market pressures, the company's collaboration with Daiichi Sankyo was highlighted by the announcement of successful phase 3 trial results for ENHERTU, which positively impacts the ...

In this article, we are going to take a look at where Recon Technology, Ltd. (NASDAQ:RCON) stands against other energy stocks that are crashing this week. After an encouraging start to the year ...